Author's response to reviews

Title: Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial.

Authors:

Wolfgang M Marx (wolf.marx@uqconnect.edu.au)
Liz Isenring (e.isenring@uq.edu.au)
Avni Sali (asali@niim.com.au)
Karin Ried (karinried@niim.com.au)
Luis Vitetta (l.vitetta@uq.edu.au)
Damien Thomson (Damien.Thomson@health.qld.gov.au)
Alexandra McCarthy (al.mccarthy@qut.edu.au)
Daniel Mckavanagh (Daniel.Mckavanagh@health.qld.gov.au)

Version: 2
Date: 24 January 2014

Author's response to reviews: see over
Dear Mr Prozenko and the editorial staff of Biomed Central,

We thank you for the valuable feedback that the reviewers have provided and have amended our manuscript to adhere to these recommendations. The changes to our manuscript are documented below:

1. **Abstract:** Please, rewrite the discussion section of your abstract to match the limitations indicated in the body of the manuscript.
   We have amended the abstract to detail the limitations discussed within the introduction while adhering to the word limit.

2. **As delayed nausea/vomiting is the primary outcome are there any plans on stratifying participants based on being prescribed aprepitant? If no, what is the justification for not doing this?**
   
   There are no plans to stratify by aprepitant and it is anticipated that the randomisation process will account for this. If there is an uneven distribution for those receiving aprepitant this will be accounted for (adjusted) in the analyses.

3. **Add reference for Rhodes Inventory of Nausea, Vomiting and Retching**
   A reference for this has been added.

4. **In the discussion section, first paragraph once again it needs to be rewritten to match your introduction. You mention “inconsistent use of standardised ginger extracts and validated assessments tools” but those are not the topics you mention and discuss above.**
   We have added two sections to the introduction that discuss these two issues both in previous studies and how our trial will aim to control for these factors.

5. **It would be helpful to other researches if the entire CINV susceptibility questionnaire was included in the manuscript as it is not available elsewhere**
   
   **Response** Thank you for your interest and this is now included

We hope that these changes are acceptable and if you require any further clarification, please do not hesitate to contact us.

Sincerely,

Wolfgang Marx